More importantly, the LI protocol improved insulin sensitivity, reduced fasting insulinemia, improve the level of the obesity-related adiponectin, decreased the level of the pro-inflammatory marker TNF-alpha and Il-6, and positively modulated the levels of exercise-induced myokines, irisin and BDNF. The gene discussed is FNDC5; the disease is obesity disorder.